nach oben

Archives of Gynecology and Obstetrics

Erschienen in:

10.06.2024 | Review

Association between body mass index and lymph node metastasis among women with cervical cancer: a systematic review and network meta-analysis

verfasst von: Tiantian Shen, Si Sun, Wenhan Li, Xiaoman Wang, Yumei Gao, Qiang Yang, Jing Cai

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Lymph node status is a determinant of survival in patients with early-stage cervical cancer. However, the relationship between obesity and lymph node status remains unclear. Therefore, this systematic review aims to evaluate the correlation between body mass index (BMI) and lymph node metastasis in cervical cancer.

Methods

Cohort studies through six databases were reviewed until December 2021. Odds ratios (ORs) for lymphatic metastasis were estimated using random-effects models and network meta-analysis. BMI groups for lymph node metastasis were ranked. Heterogeneities were assessed using I². Subgroup analyses were performed to determine possible sources of heterogeneity.

Results

No significant difference was found between obese (BMI ≥ 25) and non-obese patients (BMI < 25) (OR = 1.01; 95% CI 0.69–1.47; P = 0.97). In subgroup analyses, obesity was associated with higher risk among the Americans and advanced-stage patients. The grouping analysis based on BMI and the rankogram values revealed that the ‘35 ≤ BMI’ group had the highest risk of lymph node metastasis.

Conclusion

Although there were no significant differences in lymph node metastasis between obese and non-obese cervical cancer patients in overall analysis, patients with BMI ≥ 35 were at significantly higher risk of lymph node metastasis.

Nur mit Berechtigung zugänglich

Lobstein T, Brinsden H, Neveux M (2022) World obesity Atlas. https://www.worldobesity.org/resources/resource-library/world-obesity-atlas-20222022

Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A et al (2017) Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med 377:13–27. https://doi.org/10.1056/NEJMoa1614362CrossRefPubMed

Haslam DW, James WP (2005) Obesity. Lancet (London, England) 366:1197–1209. https://doi.org/10.1016/s0140-6736(05)67483-1CrossRefPubMed

Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638. https://doi.org/10.1056/NEJMoa021423CrossRefPubMed

Research WCRFIAIfC (2012) Diet, nutrition, physical activity and cancer: a global perspective. https://www.wcrf.org/dietandcancer

Liu XZ, Pedersen L, Halberg N (2021) Cellular mechanisms linking cancers to obesity. Cell Stress 5:55–72CrossRefPubMedPubMedCentral

Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH (2009) The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 9:88. https://doi.org/10.1186/1471-2458-9-88CrossRefPubMedPubMedCentral

von Gruenigen VE, Tian C, Frasure H, Waggoner S, Keys H, Barakat RR (2006) Treatment effects, disease recurrence, and survival in obese women with early endometrial carcinoma : a gynecologic oncology group study. Cancer 107:2786–2791. https://doi.org/10.1002/cncr.22351CrossRef

Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM et al (2012) Appropriate chemotherapy dosing for obese adult patients with cancer: american society of clinical oncology clinical practice guideline. J clin oncol 30:1553–1561. https://doi.org/10.1200/jco.2011.39.9436CrossRefPubMed

10.

Pichon B, Thureau S, Delpon G, Barillot I, Mahé MA (2013) Obesity and radiation: technical difficulties, toxicity and efficacy. Cancer Radiother 17:543–548. https://doi.org/10.1016/j.canrad.2013.06.034CrossRefPubMed

11.

Lennon H, Sperrin M, Badrick E, Renehan AG (2016) The obesity paradox in cancer: a review. Curr Oncol Rep 18:56. https://doi.org/10.1007/s11912-016-0539-4CrossRefPubMedPubMedCentral

12.

Richtig G, Hoeller C, Wolf M, Wolf I, Rainer BM, Schulter G et al (2018) Body mass index may predict the response to ipilimumab in metastatic melanoma: an observational multi-centre study. PLoS ONE 13:e0204729. https://doi.org/10.1371/journal.pone.0204729CrossRefPubMedPubMedCentral

13.

Choi Y, Park B, Jeong BC, Seo SI, Jeon SS, Choi HY et al (2013) Body mass index and survival in patients with renal cell carcinoma: a clinical-based cohort and meta-analysis. Int J Cancer 132:625–634. https://doi.org/10.1002/ijc.27639CrossRefPubMed

14.

Zhang X, Liu Y, Shao H, Zheng X (2017) Obesity paradox in lung cancer prognosis: evolving biological insights and clinical implications. J Thorac Oncol 12:1478–1488. https://doi.org/10.1016/j.jtho.2017.07.022CrossRefPubMed

15.

Li S, Wang Z, Huang J, Fan J, Du H, Liu L et al (2017) Systematic review of prognostic roles of body mass index for patients undergoing lung cancer surgery: does the ‘obesity paradox’ really exist? Eur J Cardiothorac Surg 51:817–828. https://doi.org/10.1093/ejcts/ezw386CrossRefPubMed

16.

Brunner AM, Sadrzadeh H, Feng Y, Drapkin BJ, Ballen KK, Attar EC et al (2013) Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia. Am J Hematol 88:642–646. https://doi.org/10.1002/ajh.23462CrossRefPubMedPubMedCentral

17.

Carson KR, Bartlett NL, McDonald JR, Luo S, Zeringue A, Liu J et al (2012) Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma. J clin oncol 30:3217–3222. https://doi.org/10.1200/jco.2011.39.2100CrossRefPubMedPubMedCentral

18.

Weiss L, Melchardt T, Habringer S, Boekstegers A, Hufnagl C, Neureiter D et al (2014) Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma. Ann Oncol 25:171–176. https://doi.org/10.1093/annonc/mdt481CrossRefPubMed

19.

Singla P, Bardoloi A, Parkash AA (2010) Metabolic effects of obesity: a review. World J Diabetes 1:76–88. https://doi.org/10.4239/wjd.v1.i3.76CrossRefPubMedPubMedCentral

20.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660CrossRefPubMed

21.

Gien LT, Covens A (2009) Lymph node assessment in cervical cancer: prognostic and therapeutic implications. J Surg Oncol 99:242–247. https://doi.org/10.1002/jso.21199CrossRefPubMed

22.

Cai J, He X, Wang H, Dong W, Zhang Y, Zhao J et al (2021) Topographic distribution of lymph node metastasis in patients with stage IB1 cervical cancer: an analysis of 8314 lymph nodes. Radiat oncol (London, England) 16:54. https://doi.org/10.1186/s13014-021-01781-xCrossRef

23.

24.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188. https://doi.org/10.1016/0197-2456(86)90046-2CrossRefPubMed

25.

Hutton B, Salanti G, Chaimani A, Caldwell DM, Schmid C, Thorlund K et al (2014) The quality of reporting methods and results in network meta-analyses: an overview of reviews and suggestions for improvement. PLoS ONE 9:e92508. https://doi.org/10.1371/journal.pone.0092508CrossRefPubMedPubMedCentral

26.

Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560. https://doi.org/10.1136/bmj.327.7414.557CrossRefPubMedPubMedCentral

27.

Frumovitz M, Jhingran A, Soliman PT, Klopp AH, Schmeler KM, Eifel PJ (2014) Morbid obesity as an independent risk factor for disease-specific mortality in women with cervical cancer. Obstet Gynecol 124:1098–1104. https://doi.org/10.1097/aog.0000000000000558CrossRefPubMedPubMedCentral

28.

Frumovitz M, Sun CC, Jhingran A, Schmeler KM, Dos Reis R, Milam MR et al (2008) Radical hysterectomy in obese and morbidly obese women with cervical cancer. Obstet Gynecol 112:899–905. https://doi.org/10.1097/AOG.0b013e3181863280CrossRefPubMed

29.

Kizer NT, Thaker PH, Gao F, Zighelboim I, Powell MA, Rader JS et al (2011) The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy. Cancer 117:948–956. https://doi.org/10.1002/cncr.25544CrossRefPubMed

30.

Leetanaporn K, Hanprasertpong J (2019) Impact of obesity on clinical outcomes in patients with early-stage cervical cancer after radical hysterectomy with pelvic node dissection. Oncol res treatment 42:553–563. https://doi.org/10.1159/000502752CrossRef

31.

Legge F, Margariti PA, Lucidi A, Macchia G, Petrillo M, Iannone V et al (2013) Completion surgery after concomitant chemoradiation in obese women with locally advanced cervical cancer: evaluation of toxicity and outcome measures. Acta oncologica (Stockholm, Sweden) 52:166–173. https://doi.org/10.3109/0284186x.2012.698753CrossRefPubMed

32.

Ezzati M (2016) Trends in adult body-mass index in 200 countries from, 1975 to 2014 a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. The Lancet: London. 387(10026):1377–1396CrossRef

33.

Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ et al (2011) National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet (London, England) 377:557–567. https://doi.org/10.1016/s0140-6736(10)62037-5CrossRefPubMed

34.

Maruthur NM, Bolen SD, Brancati FL, Clark JM (2009) The association of obesity and cervical cancer screening: a systematic review and meta-analysis. Obesity (Silver Spring) 17:375–381. https://doi.org/10.1038/oby.2008.480CrossRefPubMed

35.

Wong JR, Gao Z, Merrick S, Wilson P, Uematsu M, Woo K et al (2009) Potential for higher treatment failure in obese patients: correlation of elevated body mass index and increased daily prostate deviations from the radiation beam isocenters in an analysis of 1465 computed tomographic images. Int J Radiat Oncol Biol Phys 75:49–55. https://doi.org/10.1016/j.ijrobp.2008.07.049CrossRefPubMed

36.

Millender LE, Aubin M, Pouliot J, Shinohara K, Roach M 3rd (2004) Daily electronic portal imaging for morbidly obese men undergoing radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 59:6–10. https://doi.org/10.1016/j.ijrobp.2003.12.027CrossRefPubMed

37.

Rosner GL, Hargis JB, Hollis DR, Budman DR, Weiss RB, Henderson IC et al (1996) Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol 14:3000–3008. https://doi.org/10.1200/jco.1996.14.11.3000CrossRefPubMed

38.

Shachar SS, Williams GR (2017) The obesity paradox in cancer-moving beyond BMI-response. Cancer Epidemiol Biomark Prev 26:981. https://doi.org/10.1158/1055-9965.Epi-17-0144CrossRef

39.

Wang Z, Aguilar EG, Luna JI, Dunai C, Khuat LT, Le CT et al (2019) Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med 25:141–151. https://doi.org/10.1038/s41591-018-0221-5CrossRefPubMed

40.

Lohmann AE, Soldera SV, Pimentel I, Ribnikar D, Ennis M, Amir E et al (2021) Association of obesity with breast cancer outcome in relation to cancer subtypes: a meta-analysis. J Natl Cancer Inst 113:1465–1475. https://doi.org/10.1093/jnci/djab023CrossRefPubMedPubMedCentral

41.

Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D (2007) Cancer incidence and mortality in relation to body mass index in the million women study: cohort study. BMJ 335:1134. https://doi.org/10.1136/bmj.39367.495995.AECrossRefPubMedPubMedCentral

42.

Shaikh H, Bradhurst P, Ma LX, Tan SYC, Egger SJ, Vardy JL (2020) Body weight management in overweight and obese breast cancer survivors. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD012110.pub2CrossRefPubMedPubMedCentral

43.

Simillis C, Taylor B, Ahmad A, Lal N, Afxentiou T, Powar MP et al (2022) A systematic review and meta-analysis assessing the impact of body mass index on long-term survival outcomes after surgery for colorectal cancer. Eur J Cancer 172:237–251. https://doi.org/10.1016/j.ejca.2022.05.020CrossRefPubMed

44.

Li Y, Li C, Wu G, Yang W, Wang X, Duan L et al (2022) The obesity paradox in patients with colorectal cancer: a systematic review and meta-analysis. Nutr Rev 80:1755–1768. https://doi.org/10.1093/nutrit/nuac005CrossRefPubMed

45.

Kichenadasse G, Miners JO, Mangoni AA, Rowland A, Hopkins AM, Sorich MJ (2020) association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer. JAMA Oncol 6:512–518. https://doi.org/10.1001/jamaoncol.2019.5241CrossRefPubMed

46.

Naik GS, Waikar SS, Johnson AEW, Buchbinder EI, Haq R, Hodi FS et al (2019) Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition. J Immunother Cancer 7:89. https://doi.org/10.1186/s40425-019-0512-5CrossRefPubMedPubMedCentral

47.

Albiges L, Hakimi AA, Xie W, McKay RR, Simantov R, Lin X et al (2016) Body mass index and metastatic renal cell carcinoma: clinical and biological correlations. J Clin Oncol 34:3655–3663. https://doi.org/10.1200/jco.2016.66.7311CrossRefPubMedPubMedCentral

48.

Murphy WJ, Longo DL (2019) The surprisingly positive association between obesity and cancer immunotherapy efficacy. JAMA 321:1247–1248. https://doi.org/10.1001/jama.2019.0463CrossRefPubMed

49.

Ahmed M, von Itzstein MS, Sheffield T, Khan S, Fattah F, Park JY et al (2021) Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors. J Immunother Cancer. https://doi.org/10.1136/jitc-2021-002349CrossRefPubMedPubMedCentral

50.

Hao J, Zhang Y, Yan X, Yan F, Sun Y, Zeng J et al (2018) circulating adipose fatty acid binding protein is a new link underlying obesity-associated breast/mammary tumor development. Cell Metab 28:689-705.e5. https://doi.org/10.1016/j.cmet.2018.07.006CrossRefPubMedPubMedCentral

51.

Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR et al (2011) Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 17:1498–1503. https://doi.org/10.1038/nm.2492CrossRefPubMedPubMedCentral

52.

Wu Q, Li B, Li Z, Li J, Sun S, Sun S (2019) Cancer-associated adipocytes: key players in breast cancer progression. J Hematol Oncol 12:95. https://doi.org/10.1186/s13045-019-0778-6CrossRefPubMedPubMedCentral

53.

Dirat B, Bochet L, Dabek M, Daviaud D, Dauvillier S, Majed B et al (2011) Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Can Res 71:2455–2465. https://doi.org/10.1158/0008-5472.Can-10-3323CrossRef

54.

Kolb R, Kluz P, Tan ZW, Borcherding N, Bormann N, Vishwakarma A et al (2019) Obesity-associated inflammation promotes angiogenesis and breast cancer via angiopoietin-like 4. Oncogene 38:2351–2363. https://doi.org/10.1038/s41388-018-0592-6CrossRefPubMed

55.

Rybinska I, Agresti R, Trapani A, Tagliabue E, Triulzi T (2020) Adipocytes in breast cancer, the thick and the thin. Cells. https://doi.org/10.3390/cells9030560CrossRefPubMedPubMedCentral

56.

Martinez-Outschoorn UE, Lin Z, Whitaker-Menezes D, Howell A, Sotgia F, Lisanti MP (2012) Ketone body utilization drives tumor growth and metastasis. Cell Cycle 11:3964–3971. https://doi.org/10.4161/cc.22137CrossRefPubMedPubMedCentral

57.

Wang YY, Attané C, Milhas D, Dirat B, Dauvillier S, Guerard A et al (2017) Mammary adipocytes stimulate breast cancer invasion through metabolic remodeling of tumor cells. JCI Insight 2:e87489. https://doi.org/10.1172/jci.insight.87489CrossRefPubMedPubMedCentral

58.

Thomas DD, Corkey BE, Istfan NW, Apovian CM (2019) Hyperinsulinemia: an early indicator of metabolic dysfunction. J Endocr Soc 3:1727–1747. https://doi.org/10.1210/js.2019-00065CrossRefPubMedPubMedCentral

59.

Ireland L, Santos A, Campbell F, Figueiredo C, Hammond D, Ellies LG et al (2018) Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer. Oncogene 37:2022–2036. https://doi.org/10.1038/s41388-017-0115-xCrossRefPubMedPubMedCentral

60.

Incio J, Liu H, Suboj P, Chin SM, Chen IX, Pinter M et al (2016) Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy. Cancer Discov 6:852–869. https://doi.org/10.1158/2159-8290.Cd-15-1177CrossRefPubMedPubMedCentral

61.

Lazar I, Clement E, Dauvillier S, Milhas D, Ducoux-Petit M, LeGonidec S et al (2016) Adipocyte exosomes promote melanoma aggressiveness through fatty acid oxidation: a novel mechanism linking obesity and cancer. Can Res 76:4051–4057. https://doi.org/10.1158/0008-5472.Can-16-0651CrossRef

62.

Balaban S, Shearer RF, Lee LS, van Geldermalsen M, Schreuder M, Shtein HC et al (2017) Adipocyte lipolysis links obesity to breast cancer growth: adipocyte-derived fatty acids drive breast cancer cell proliferation and migration. Cancer Metab 5:1. https://doi.org/10.1186/s40170-016-0163-7CrossRefPubMedPubMedCentral

63.

Kuo CY, Ann DK (2018) When fats commit crimes: fatty acid metabolism, cancer stemness and therapeutic resistance. Cancer Commun (Lond) 38:47. https://doi.org/10.1186/s40880-018-0317-9CrossRefPubMed

64.

Du Q, Liu P, Zhang C, Liu T, Wang W, Shang C et al (2022) FASN promotes lymph node metastasis in cervical cancer via cholesterol reprogramming and lymphangiogenesis. Cell Death Dis 13:488. https://doi.org/10.1038/s41419-022-04926-2CrossRefPubMedPubMedCentral

65.

Zhang C, Liao Y, Liu P, Du Q, Liang Y, Ooi S et al (2020) FABP5 promotes lymph node metastasis in cervical cancer by reprogramming fatty acid metabolism. Theranostics 10:6561–6580. https://doi.org/10.7150/thno.44868CrossRefPubMedPubMedCentral

66.

Li B, Sui L (2021) Metabolic reprogramming in cervical cancer and metabolomics perspectives. Nutr Metab (Lond) 18:93. https://doi.org/10.1186/s12986-021-00615-7CrossRefPubMed

Titel: Association between body mass index and lymph node metastasis among women with cervical cancer: a systematic review and network meta-analysis
verfasst von: Tiantian Shen
Si Sun
Wenhan Li
Xiaoman Wang
Yumei Gao
Qiang Yang
Jing Cai
Publikationsdatum: 10.06.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 3/2024
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-024-07528-9

Maternal and perinatal infectious morbidity in term prelabor rupture of membrane according to two induction of labor protocols

Maternal-Fetal Medicine

Correction: Selection of prenatal screening with nuchal translucency > 95th centile and below 99th centile: a 4-year observational study with real-world data

Correction

A plea for reader-friendly description of statistics used in clinical journal articles

Correspondence

Screening for perinatal depression and stress: a prospective cohort study

Maternal-Fetal Medicine

Expression of Concern: Carbetocin versus sublingual misoprostol plus oxytocin infusion for prevention of postpartum hemorrhage at cesarean section in patients with risk factors: a randomized, open trail study

Editorial Expression of Concern

Advanced maternal age (AMA) and pregnancy: a feasible but problematic event

Review

Neu im Fachgebiet Gynäkologie und Geburtshilfe

KI-gestütztes Mammografiescreening überzeugt im Praxistest

16.01.2025
Künstliche Intelligenz im Gesundheitswesen
Nachrichten

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Einer von sieben Frauen macht die Menopause sehr zu schaffen

15.01.2025
Menopause
Nachrichten

Von mäßigen bis schweren vasomotorischen Beschwerden sind 14,7% der Frauen in der Postmenopause betroffen. Das haben kanadische Forscherinnen in einer Subgruppenanalyse der WARM-Studie herausgefunden.

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

12.01.2025
Elektronische Patientenakte
Nachrichten

Am 15. Januar geht die „ePA für alle“ zunächst in den Modellregionen an den Start. Doch schon bald soll sie in allen Praxen zum Einsatz kommen. Was ist jetzt zu tun? Was müssen Sie wissen? Wir geben in einem FAQ Antworten auf 21 Fragen.

Keine eingeschränkten Kassenleistungen bei Schwangerschaft nach IVF

Medikamente in Schwangerschaft und Stillzeit
Nachrichten

Nach privat bezahlter In-vitro-Fertilisation muss die gesetzliche Krankenkasse ein Arzneimittel zum Erhalt der Schwangerschaft bezahlen, so ein Urteil des Sozialgerichts in München.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Association between body mass index and lymph node metastasis among women with cervical cancer: a systematic review and network meta-analysis